Using GFR, Albuminuria, and Their Changes in Clinical Trials and Clinical Care

被引：6
|
作者：
Coresh, Josef [1 ,2 ]
Grams, Morgan E. [1 ,2 ]
Chen, Teresa K. [2 ]
机构：
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD 21205 USA
[2] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA
来源：
AMERICAN JOURNAL OF KIDNEY DISEASES | 2021年 / 78卷 / 03期
关键词：
DECLINE;
D O I：
10.1053/j.ajkd.2021.04.003
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：333 / 334
页数：2
相关论文
共 50 条
  • [1] Combination of Changes in Estimated GFR and Albuminuria and the Risk of Major Clinical Outcomes
    Ohkuma, Toshiaki
    Jun, Min
    Chalmers, John
    Cooper, Mark E.
    Hamet, Pavel
    Harrap, Stephen
    Zoungas, Sophia
    Perkovic, Vlado
    Woodward, Mark
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2019, 14 (06): : 862 - 872
  • [2] Changes in GFR and Albuminuria in Routine Clinical Practice and the Risk of Kidney Disease Progression
    Neuen, Brendon L.
    Weldegiorgis, Misghina
    Herrington, William G.
    Ohkuma, Toshiaki
    Smith, Margaret
    Woodward, Mark
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2021, 78 (03) : 350 - +
  • [3] Change in Estimated GFR and Albuminuria as End Points in Clinical Trials: A Viewpoint From the FDA
    Thompson, Aliza
    Smith, Kimberly
    Lawrence, John
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2020, 75 (01) : 4 - 5
  • [4] Change in Estimated GFR and Albuminuria as End Points in Clinical Trials: A Perspective of People Living With Kidney Disease
    Baliker, Mary
    Bressler, Kent
    Forfang, Derek
    Fowler, Kevin J.
    Grandinetti, Amanda
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2020, 75 (01) : 9 - 10
  • [5] Albuminuria: a target for clinical trials in kidney disease?
    Glassock, Richard J.
    [J]. NATURE REVIEWS NEPHROLOGY, 2019, 15 (05) : 257 - 258
  • [6] Albuminuria: a target for clinical trials in kidney disease?
    Richard J. Glassock
    [J]. Nature Reviews Nephrology, 2019, 15 : 257 - 258
  • [7] Change in Albuminuria and Estimated GFR as End Points for Clinical Trials in Early Stages of CKD: A Perspective From European Regulators
    Holtkamp, Frank
    Gudmundsdottir, Hrefna
    Maciulaitis, Romaldas
    Benda, Norbert
    Thomson, Andrew
    Vetter, Thorsten
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2020, 75 (01) : 6 - 8
  • [8] Change in Albuminuria and GFR Slope as Joint Surrogate End Points for Kidney Failure: Implications for Phase 2 Clinical Trials in CKD
    Heerspink, Hiddo J. L. A.
    Inker, Lesley
    Tighiouart, Hocine H.
    Collier, Willem
    Haaland, Benjamin
    Luo, Jiyu B.
    Appel, Gerald
    Chan, Tak Mao O.
    Estacio, Raymond
    Fervenza, Fernando
    Floege, Juergen
    Imai, Enyu H.
    Jafar, Tazeen B.
    Lewis, Julia
    Li, Philip Kam-Tao
    Locatelli, Francesco D.
    Maes, Bart
    Perna, Annalisa D.
    Perrone, Ronald
    Praga, Manuel P.
    Schena, Francesco
    Wanner, Christoph
    Xie, Di
    Greene, Tom
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2023, 34 (06): : 955 - 968
  • [9] GFR slope as a surrogate endpoint for CKD progression in clinical trials
    Inker, Lesley A.
    Chaudhari, Juhi
    [J]. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2020, 29 (06): : 581 - 590
  • [10] Number and Frequency of Albuminuria Measurements in Clinical Trials in Diabetic Nephropathy
    Kropelin, Tobias F.
    de Zeeuw, Dick
    Andress, Dennis L.
    Bijlsma, Maarten J.
    Persson, Frederik
    Parving, Hans-Henrik
    Heerspink, Hiddo J. Lambers
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2015, 10 (03): : 410 - 416
12345